Dr. Lianne Kearsley-Fleet
University of Manchester
Research Associate, Medicine And Medical Sciences
United Kingdom
Find me at
My Publications
Adults with Juvenile Idiopathic Arthritis on TNFi therapy in the United Kingdom.
RMD Open
October 2016
Many children who have juvenile idiopathic arthritis (JIA) continue to have disease as adults. TNF inhibitors (TNFi) have already been shown to be an effective treatment for children with JIA when ...
Choice of biologics for children with juvenile idiopathic arthritis in the United Kingdom.
Rheumatology
January 2016
Etanercept is often the first choice biologic in the treatment of JIA, however there may be occasions where etanercept is not the preferred choice. Recent studies have reported that other biologic ...
One year of treatment with etanercept (Enbrel) in children with juvenile idiopathic art...
Rheumatology
December 2015
The aims of this study were to look at whether disease activity in children with juvenile idiopathic arthritis improved after one year of treatment with etanercept, and if so, which patients were m...
Use and effectiveness of rituximab in children and young people with JIA
Rheumatology
October 2018
What was already known? Rituximab is not licensed for use in children and young people with juvenile idiopathic arthritis (JIA). However, it is considered a possible treatment option particularly i...
Improved disease activity in patients with systemic JIA treated with tocilizumab or ana...
Rheumatology
August 2018
What was already known? Biologic therapy is usually given to patients with juvenile idiopathic arthritis (JIA) after they have failed to respond or do not tolerant methotrexate. Patients with syste...
Identifying treatment refractory disease in people with rheumatoid arthritis
Annals of the Rheumatic Diseases
July 2018
What was already known? Biologic therapies have revolutionised treatment and outcomes for people with rheumatoid arthritis (RA). Over the years many different types of biologic therapies have becom...
Height change in children with juvenile idiopathic arthritis after two years of etanerc...
Rheumatology
January 2015
Juvenile idiopathic arthritis (JIA) affects approximately 1 in 1000 children in the UK, with disease often continuing into adulthood. Children with JIA can experience delayed and restricted growth,...
Methotrexate remains an effective treatment for JIA, although nausea is common
Rheumatology
March 2019
What was already known? Methotrexate is the current recommended first-line therapy for children and young people with juvenile idiopathic arthritis (JIA). It is generally considered an effective tr...
Which biologic drugs are used, and how well do they work, in children and young people ...
The Lancet Rheumatology
March 2020
Juvenile idiopathic arthritis (JIA) is a painful debilitating inflammatory arthritis affecting children and young people. Biologic therapies have become a main treatment option of children and youn...
Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach
Drugs
May 2020
Refractory rheumatoid arthritis (RA) has emerged as an area of unmet need in a landscape of generally well-controlled disease. Whilst most patients are adequately treated on methotrexate and other ...
Children and young people with arthritis… What other diseases do they have?
Rheumatology
October 2021
What is already known? Not much is known about what other diseases or medical conditions children and young people with arthritis (JIA) have, and how often they occur. Large international registrie...
Children and young people with arthritis are not at high risk of severe COVID-19.
Annals of the Rheumatic Diseases
March 2022
Children and young people appear to be less affected, compared with adults, by severe COVID-19, with most experiencing mild symptoms, or even no symptoms at all. However, some adults with rheumatic...
If you stop biologic therapy for remission, are you likely to remain off treatment?
Rheumatology
September 2022
Juvenile idiopathic arthritis (JIA) is a painful debilitating inflammatory arthritis affecting children and young people. Biologic therapies are the main treatment for selected categories of childr...
Association Between Race/Ethnicity and <scp>COVID</scp> ‐19 Out...
Arthritis Care & Research
October 2022
Continuing specialist care into adulthood in young people with juvenile idiopathic arth...
Rheumatology
September 2022
Development and external validation of a model predicting new‐onset chronic uveitis at ...
Arthritis & Rheumatology
August 2022
Development of a Prediction Model for <scp>COVID</scp> ‐19 Acut...
ACR Open Rheumatology
July 2022
Environmental and societal factors associated with COVID-19-related death in people wit...
The Lancet Rheumatology
July 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846...
Annals of the Rheumatic Diseases
June 2022
Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drug...
Rheumatology
March 2022
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lup...
Annals of the Rheumatic Diseases
February 2022
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal d...
Annals of the Rheumatic Diseases
December 2021
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheuma...
The Lancet Rheumatology
November 2021
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 sev...
Annals of the Rheumatic Diseases
May 2021
Factors associated with COVID-19-related death in people with rheumatic diseases: resul...
Annals of the Rheumatic Diseases
January 2021
Risk of uveitis in patients with JIA receiving etanercept: challenges of analysing real...
Rheumatology
October 2019
Cervical screening attendance and results for women with rheumatoid arthritis in England
Rheumatology
August 2019
Moderate disease does not necessarily mean moderate disability
PLoS ONE
May 2019
Cancers and deaths in patients with severe psoriatic arthritis on TNF-inhibitor treatment.
Rheumatology
August 2018
Long-term rituximab treatment in patients with rheumatoid arthritis
Rheumatology
March 2018
TNF inhibitors and dementia in patients with rheumatoid arthritis
International Journal of Geriatric Psychiatry
February 2018
Long-term TNF-inhibitor treatment in patients with psoriatic arthritis
RMD Open
January 2018
How common is remission in juvenile idiopathic arthritis?
Seminars in Arthritis and Rheumatism
December 2017
Patterns of height growth in patients with juvenile idiopathic arthritis.
Seminars in Arthritis and Rheumatism
November 2017
Registries and cohort studies around the world in juvenile idiopathic arthritis.
Pediatric Rheumatology
April 2017
Effect of Rituximab on pregnancy outcome in women with Rheumatoid Arthritis
Rheumatology
January 2017
Lupus and vasculitis‐like events in patients with rheumatoid arthritis treated with TNF...
RMD Open
January 2017
Tocilizumab in patients with rheumatoid arthritis in the United Kingdom
Clinical Rheumatology
December 2016
Mortality in juvenile idiopathic arthritis - increased in systemic juvenile idiopathic ...
Archives of Disease in Childhood
October 2016
Cancer in patients with RA receiving TNF inhibitors or rituximab with prior malignancy
Rheumatology
August 2016
Risk of pneumonia infection in patients with rheumatoid arthritis treated with TNFis
Rheumatology
April 2016
Discovery of recent swine infectious agents.
Veterinary Research
September 2015
Infections in children with juvenile idiopathic arthritis treated with etanercept.
Arthritis & Rheumatology
August 2015
Comparing patients with Rheumatoid Arthritis in European biologic registers
Rheumatology
November 2014
Canine epilepsy in the UK - how common is it and which dogs are at risk?
Veterinary Record
January 2013
